Application of color doppler ultrasound to evaluate chemotherapeutic effect on primary thyroid lymphoma

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Primary thyroid lymphoma (PTL) is a rare disease which responds well to rituximab-based chemotherapy. Here, we describe a case who was diagnosed through core needle biopsy as having diffuse large B-cell lymphoma in the right lobe of thyroid gland. Positron emission tomography computed tomography (PET-CT) revealed no other foci of hot spots, so PTL was considered. She was treated with rituximab plus bendamustine for three cycles, and color Doppler ultrasound revealed significant reduction of blood flow signals in the tumor but no significant decrease of its size (<25% extent). Then, the chemotherapy regimen was adjusted to rituximab, cyclophosphamide, vincristine, prednisone (R-COP), and complete remission was noted on ultrasound and PET-CT after three cycles of R-COP treatment. This case is reported to tell that color Doppler ultrasound, in addition to PET-CT, is useful to evaluate chemotherapeutic effect on PTLs.

Cite

CITATION STYLE

APA

Hu, C. C., Wang, C. W., & Chen, J. H. (2021). Application of color doppler ultrasound to evaluate chemotherapeutic effect on primary thyroid lymphoma. Journal of Medical Ultrasound, 29(1), 60–63. https://doi.org/10.4103/JMU.JMU_15_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free